Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting

Pharmacological Research

Volumn 49, Issue 3, 2004, Pages 275-281

  Kikura, Mutsuhito ^a   Morita, Koji ^a   Sato, Shigehito ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Colforsin daropate; Inotropic vasodilator; Pharmacokinetic simulation; Pharmacokinetics

Indexed keywords

6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; DRUG METABOLITE; FORSKOLIN DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; GAS CHROMATOGRAPHY; HEART VENTRICLE FAILURE; HUMAN; MALE; PRIORITY JOURNAL; SIMULATION; TREATMENT INDICATION;

EID: 0347320613     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.09.012     Document Type: Article

References (11)

1. Hosono M., Takahira T., Fujita A., Fujihara R., Ishizuka O., Tatee T. Cardiovascular and adenylate cyclase stimulant properties of NKH477, a novel water-soluble forskolin derivative. J. Cardiovasc. Pharmacol. 19(4):1992;625-634.
2. Ishizuka O., Hosono M., Nakamura K. Profile of cardiovascular effects of NKH477, a novel forskolin derivative, assessed in isolated, blood-perfused dog heart preparations: comparison with isoproterenol. J. Cardiovasc. Pharmacol. 20(2):1992;261-267.
3. Fujita A., Takahira T., Hosono M., Nakamura K. Improvement of drug-induced cardiac failure by NKH477, a novel forskolin derivative, in the dog heart-lung preparation. Jpn. J. Pharmacol. 58(4):1992;375-381.
4. Shafiq J., Suzuki S., Itoh T., Kuriyama H. Mechanisms of vasodilation induced by NKH477, a water-soluble forskolin derivative, in smooth muscle of the porcine coronary artery. Circ. Res. 71(1):1992;70-81.
5. Mori M., Takeuchi M., Takaoka H., Hata K., Hayashi Y., Yokoyama M. Effect of NKH477, a new water-soluble forskolin derivative, on arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction: comparison with dobutamine. J. Cardiovasc. Pharmacol. 24(2):1994;310-316.
6. Holley F.O., Ponganis K.V., Stanski D.R. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin. Pharmacokinet. 7(3):1982;234-251.
7. Kametani S., Matsumoto S., Takahira T., Hosono M., Hashimoto Y., Horinishi H. The pharmacodynamics of 6-(3-dimethylaminopropionyl)forskolin and a possible metabolite in beagles. J. Pharm. Sci. 85(4):1996;377-380.
8. Sheiner L.B., Beal S.L. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J. Pharmacokinet. Biopharm. 13(2):1985;185-201.
9. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.
10. Bristow M.R., Port J.D., Hershberger R.E., Gilbert E.M., Feldman A.M. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur. Heart J. 10(Suppl. B):1989;45-54.
11. Burden RL, Faires BA. Numerical analysis. Boston: Prindel, Weber, and Schmidt; 1985.